Barclays has adjusted its price target for Elevance Health (ELV, Financial), raising it from $512 to $522. The update comes in light of Elevance Health’s recent first-quarter performance. Alongside this revision, Barclays maintains its Overweight rating for the company's shares, indicating continued confidence in its positive market positioning and future growth potential.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 19 analysts, the average target price for Elevance Health Inc (ELV, Financial) is $496.87 with a high estimate of $585.00 and a low estimate of $428.00. The average target implies an upside of 19.47% from the current price of $415.90. More detailed estimate data can be found on the Elevance Health Inc (ELV) Forecast page.
Based on the consensus recommendation from 24 brokerage firms, Elevance Health Inc's (ELV, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Elevance Health Inc (ELV, Financial) in one year is $622.26, suggesting a upside of 49.62% from the current price of $415.9. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Elevance Health Inc (ELV) Summary page.
